173 related articles for article (PubMed ID: 37169953)
1. Combinatorial immunotherapy with gemcitabine and ex vivo-expanded NK cells induces anti-tumor effects in pancreatic cancer.
Koh EK; Lee HR; Son WC; Park GY; Kim J; Bae JH; Park YS
Sci Rep; 2023 May; 13(1):7656. PubMed ID: 37169953
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies.
Masuyama J; Murakami T; Iwamoto S; Fujita S
Cytotherapy; 2016 Jan; 18(1):80-90. PubMed ID: 26549384
[TBL] [Abstract][Full Text] [Related]
3. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
[TBL] [Abstract][Full Text] [Related]
4. Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells.
Gürlevik E; Fleischmann-Mundt B; Brooks J; Demir IE; Steiger K; Ribback S; Yevsa T; Woller N; Kloos A; Ostroumov D; Armbrecht N; Manns MP; Dombrowski F; Saborowski M; Kleine M; Wirth TC; Oettle H; Ceyhan GO; Esposito I; Calvisi DF; Kubicka S; Kühnel F
Gastroenterology; 2016 Aug; 151(2):338-350.e7. PubMed ID: 27210037
[TBL] [Abstract][Full Text] [Related]
5. IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells.
McMichael EL; Jaime-Ramirez AC; Guenterberg KD; Luedke E; Atwal LS; Campbell AR; Hu Z; Tatum AS; Kondadasula SV; Mo X; Tridandapani S; Bloomston M; Ellison EC; Williams TM; Bekaii-Saab T; Carson WE
Clin Cancer Res; 2017 Jan; 23(2):489-502. PubMed ID: 27435400
[TBL] [Abstract][Full Text] [Related]
6. Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer.
Brooks J; Fleischmann-Mundt B; Woller N; Niemann J; Ribback S; Peters K; Demir IE; Armbrecht N; Ceyhan GO; Manns MP; Wirth TC; Kubicka S; Bernhardt G; Smyth MJ; Calvisi DF; Gürlevik E; Kühnel F
Cancer Res; 2018 Jan; 78(2):475-488. PubMed ID: 29180478
[TBL] [Abstract][Full Text] [Related]
7. A New Ex Vivo Method for Effective Expansion and Activation of Human Natural Killer Cells for Anti-Tumor Immunotherapy.
Yang H; Tang R; Li J; Liu Y; Ye L; Shao D; Jin M; Huang Q; Shi J
Cell Biochem Biophys; 2015 Dec; 73(3):723-9. PubMed ID: 27259316
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
[TBL] [Abstract][Full Text] [Related]
9. Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas.
Davis M; Conlon K; Bohac GC; Barcenas J; Leslie W; Watkins L; Lamzabi I; Deng Y; Li Y; Plate JM
J Immunother; 2012 Oct; 35(8):629-40. PubMed ID: 22996369
[TBL] [Abstract][Full Text] [Related]
10. Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self.
Michen S; Frosch J; Füssel M; Schackert G; Momburg F; Temme A
Cytotherapy; 2020 Jul; 22(7):354-368. PubMed ID: 32451262
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo-expanded natural killer cells kill cancer cells more effectively than ex vivo-expanded γδ T cells or αβ T cells.
Deng X; Terunuma H; Terunuma A; Takane T; Nieda M
Int Immunopharmacol; 2014 Oct; 22(2):486-91. PubMed ID: 25131561
[TBL] [Abstract][Full Text] [Related]
12. Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway.
Chen L; Zhou D; Liu Z; Huang X; Liu Q; Kang Y; Chen Z; Guo Y; Zhu H; Sun C
Oncol Rep; 2018 Mar; 39(3):1081-1089. PubMed ID: 29328487
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo activation and expansion of natural killer cells from patients with advanced cancer with feeder cells from healthy volunteers.
Kim EK; Ahn YO; Kim S; Kim TM; Keam B; Heo DS
Cytotherapy; 2013 Feb; 15(2):231-241.e1. PubMed ID: 23321334
[TBL] [Abstract][Full Text] [Related]
14. NK cells shape pancreatic and oral tumor microenvironments; role in inhibition of tumor growth and metastasis.
Jewett A; Kos J; Fong Y; Ko MW; Safaei T; Perišić Nanut M; Kaur K
Semin Cancer Biol; 2018 Dec; 53():178-188. PubMed ID: 30081230
[TBL] [Abstract][Full Text] [Related]
15. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.
Morgan MA; Parsels LA; Kollar LE; Normolle DP; Maybaum J; Lawrence TS
Clin Cancer Res; 2008 Aug; 14(16):5142-9. PubMed ID: 18698032
[TBL] [Abstract][Full Text] [Related]
16. The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their
Heinze A; Grebe B; Bremm M; Huenecke S; Munir TA; Graafen L; Frueh JT; Merker M; Rettinger E; Soerensen J; Klingebiel T; Bader P; Ullrich E; Cappel C
Front Immunol; 2019; 10():2816. PubMed ID: 31849984
[TBL] [Abstract][Full Text] [Related]
17. CD34
Van der Meer JMR; de Jonge PKJD; van der Waart AB; Geerlings AC; Moonen JP; Brummelman J; de Klein J; Vermeulen MC; Maas RJA; Schaap NPM; Hoogstad-van Evert JS; Ottevanger PB; Jansen JH; Hobo W; Dolstra H
Oncoimmunology; 2021; 10(1):1981049. PubMed ID: 34616589
[TBL] [Abstract][Full Text] [Related]
18. The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer.
Wagner K; Schulz P; Scholz A; Wiedenmann B; Menrad A
Clin Cancer Res; 2008 Aug; 14(15):4951-60. PubMed ID: 18676770
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions.
Jung D; Baek YS; Lee IJ; Kim KY; Jang H; Hwang S; Jung J; Moon YW; Park KS; Choi YS; An HJ
J Exp Clin Cancer Res; 2021 Oct; 40(1):333. PubMed ID: 34686187
[TBL] [Abstract][Full Text] [Related]
20. Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model.
Thangaraj JL; Ahn SY; Jung SH; Vo MC; Chu TH; Thi Phan MT; Kwon M; Lee KH; Kim M; Song GY; Yang DH; Ahn JS; Kim HJ; Cho D; Lee JJ
Cell Mol Immunol; 2021 Jul; 18(7):1652-1661. PubMed ID: 33980993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
